Studies boost for Allergan
Posters presented at shows in China and the US highlight positive results for Optive Fusion eye drops
Allergan Optive Fusion eye drops have shown rapid and continued improvement in the symptoms of dry eye in a study that was presented at the 2016 Asia Pacific Academy of Ophthalmology Congress (APAO) (24–27 March, China).
The artificial tear treatment is the latest addition to the company’s Optive range of products that has been developed by the pharmaceutical company specifically for the treatment of dry eye disease.
The range comprises Optive lubricant eye drops, Optive Plus and Optive Fusion, which combines two of the leading dry eye comfort agents, carboxymethylcellulose and sodium hyaluronate.
In the study, Clinical evaluation of a combination carboxymethylcellulose and hyaluronic acid eye drop in dry eye, the overall clinical efficacy of Optive Fusion was shown to be similar to Refresh Optive, one of Allergan’s existing eye drops for dry eye disease.
However, some differences were observed in favour of Optive Fusion compared with Refresh Optive, significantly in overall ocular pain and discomfort at day 90.
The use of Optive Fusion in a broad range of dry eye patients was further supported by another study that showed patients with evaporative dry eye disease, as well as those with acqueous-deficient dry eye disease, improved when treated with Optive Fusion for 90 days.
In the study, Definition and clinical characteristics of evaporative dry eye in a general population of dry eye patients, improvement was measured against dryness, grittiness and foreign body sensation. The abstract was presented at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) (1–5 May, Seattle).
Allergan’s Ophthalmology Business Unit director, Damon Cooke, said: “Dry eye disease is impacting increasing numbers of people as we spend more time looking at screens and living in air conditioned environments.”
He added: “Dry eye disease can have a huge effect on people’s quality of life, and is often very debilitating. As leaders in ophthalmology, we are delighted to work on new treatments which can provide relief for a condition that is too often overlooked or trivialised."
For more information, visit the Optive website.